-
Retrophin Up 40% On Kidney Disease Drug Trial, Shkreli Still Wants His $25+ Million 'Hogan Reward'
Wednesday, September 7, 2016 - 10:57am | 348Read More...Martin Shkreli, the so-called "most hated man on the Internet" is making news again. Retrophin Inc (NASDAQ: RTRX), a bio-pharmaceutical company that focuses on therapies for the treatment of rare diseases, saw its shares surge Wednesday. The company announced positive results from a...
